FTXH vs. ARKG
Compare and contrast key facts about First Trust Nasdaq Pharmaceuticals ETF (FTXH) and ARK Genomic Revolution Multi-Sector ETF (ARKG).
FTXH and ARKG are both exchange-traded funds (ETFs), meaning they are traded on stock exchanges and can be bought and sold throughout the day. FTXH is a passively managed fund by First Trust that tracks the performance of the Nasdaq U.S. Smart Pharmaceuticals Index. It was launched on Sep 20, 2016. ARKG is an actively managed fund by ARK. It was launched on Oct 31, 2014.
Performance
FTXH vs. ARKG - Performance Comparison
Loading graphics...
FTXH vs. ARKG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
FTXH First Trust Nasdaq Pharmaceuticals ETF | 5.20% | 24.15% | 2.98% | -1.41% | 2.55% | 6.14% | 11.73% | 22.13% | -9.51% | 19.44% |
ARKG ARK Genomic Revolution Multi-Sector ETF | -6.49% | 23.04% | -28.24% | 16.22% | -53.90% | -33.92% | 180.40% | 44.00% | -1.26% | 46.61% |
Returns By Period
In the year-to-date period, FTXH achieves a 5.20% return, which is significantly higher than ARKG's -6.49% return.
FTXH
- 1D
- 0.69%
- 1M
- -2.33%
- YTD
- 5.20%
- 6M
- 17.23%
- 1Y
- 31.34%
- 3Y*
- 11.55%
- 5Y*
- 7.51%
- 10Y*
- —
ARKG
- 1D
- 2.54%
- 1M
- -9.43%
- YTD
- -6.49%
- 6M
- -6.10%
- 1Y
- 34.11%
- 3Y*
- -3.42%
- 5Y*
- -21.16%
- 10Y*
- 4.95%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
FTXH vs. ARKG - Expense Ratio Comparison
FTXH has a 0.60% expense ratio, which is lower than ARKG's 0.75% expense ratio.
Return for Risk
FTXH vs. ARKG — Risk / Return Rank
FTXH
ARKG
FTXH vs. ARKG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for First Trust Nasdaq Pharmaceuticals ETF (FTXH) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| FTXH | ARKG | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.51 | 0.77 | +0.74 |
Sortino ratioReturn per unit of downside risk | 2.06 | 1.38 | +0.68 |
Omega ratioGain probability vs. loss probability | 1.27 | 1.16 | +0.12 |
Calmar ratioReturn relative to maximum drawdown | 2.17 | 1.11 | +1.06 |
Martin ratioReturn relative to average drawdown | 7.06 | 2.98 | +4.09 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading graphics...
Sharpe Ratios by Period
| FTXH | ARKG | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.51 | 0.77 | +0.74 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.47 | -0.47 | +0.94 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.12 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.38 | 0.08 | +0.30 |
Correlation
The correlation between FTXH and ARKG is 0.52, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
Dividends
FTXH vs. ARKG - Dividend Comparison
FTXH's dividend yield for the trailing twelve months is around 1.22%, while ARKG has not paid dividends to shareholders.
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
FTXH First Trust Nasdaq Pharmaceuticals ETF | 1.22% | 1.41% | 1.66% | 1.55% | 1.11% | 1.03% | 0.82% | 0.67% | 0.91% | 2.18% | 0.19% |
ARKG ARK Genomic Revolution Multi-Sector ETF | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.62% | 0.85% | 3.14% | 0.82% | 1.34% | 0.00% |
Drawdowns
FTXH vs. ARKG - Drawdown Comparison
The maximum FTXH drawdown since its inception was -32.11%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for FTXH and ARKG.
Loading graphics...
Drawdown Indicators
| FTXH | ARKG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -32.11% | -83.59% | +51.48% |
Max Drawdown (1Y)Largest decline over 1 year | -12.74% | -27.51% | +14.77% |
Max Drawdown (5Y)Largest decline over 5 years | -19.51% | -80.18% | +60.67% |
Max Drawdown (10Y)Largest decline over 10 years | — | -83.59% | — |
Current DrawdownCurrent decline from peak | -2.69% | -75.76% | +73.07% |
Average DrawdownAverage peak-to-trough decline | -5.88% | -35.32% | +29.44% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.92% | 10.24% | -6.32% |
Volatility
FTXH vs. ARKG - Volatility Comparison
The current volatility for First Trust Nasdaq Pharmaceuticals ETF (FTXH) is 6.01%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 13.41%. This indicates that FTXH experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading graphics...
Volatility by Period
| FTXH | ARKG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.01% | 13.41% | -7.40% |
Volatility (6M)Calculated over the trailing 6-month period | 11.84% | 31.90% | -20.06% |
Volatility (1Y)Calculated over the trailing 1-year period | 21.09% | 44.84% | -23.75% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 16.15% | 45.39% | -29.24% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 18.45% | 40.94% | -22.49% |